The goal of this clinical research study is to learn if ivonescimab can help to control previously treated, metastatic colorectal cancer.
Capable of giving signed informed consent
Male and female adult participants 18 years of age or older on day of signing informed consent.
Histological or cytological confirmed advanced, metastatic adenocarcinoma of colon or rectum.
Known MMR or MSI status performed by local standard of practice. (e.g., IHC and/or PCR, next-generation sequencing)
Any single liver metastasis >5.0 cm (Cohort 2 only)
Except for MSI-H/dMMR tumors, prior therapy with PD-1, PD-L1, or CTLA-4 inhibitors (Cohorts 2 and 3 only).
Patient who discontinued prior therapy with immune checkpoint inhibitors due to Grade 2 neurologic, cardiac, or ophthalmologic events or recurrent Grade 2 pneumonitis are not eligible for the trial (Cohort 1 only).
Systemic anti-cancer treatment within 14 days or less than 5 half-lives (whichever is shorter) of the first dose of study treatment.
Single group
Ivonescimab
DrugGiven by IV
1. Safety and Adverse Events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Click on the lead sponsor to view all of their trials.
M.D. Anderson Cancer Center
Lead sponsor
Akesobio Australia Pty Ltd
Collaborator
Summit Therapeutics
Collaborator
